Skip to main content
SpringerLink
Log in

Trasylol in acute pancreatitis

  • Published:
The American Journal of Digestive Diseases Aims and scope Submit manuscript

Conclusions

Trasylol in the dosage used in this trial was of no value in the treatment of acute pancreatitis. There is some evidence, both experimental and clinical, to suggest that a further double-blind trial of Trasylol using very much larger doses would be valuable. In the meanwhile, and until we have further knowledge on the matter, it would appear that if Trasylol is given for acute pancreatitis at least 200,000 U. per day should be administered. Obviously with this dosage a close watch must be kept for toxic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bedacht, R. Treatment of acute and chronic pancreatitic diseases.Arztliche. Praxis 10:1212, 1958.

    Google Scholar 

  2. Forell, M. M. Therapy with kallikrein and protease inhibitors.Ann N Y Acad Sci 104: 368, 1963.

    Google Scholar 

  3. Feey, E. K., Kraut, H., andWerle, E. Kallikrein. Enke, Stuttgart, 1950.

    Google Scholar 

  4. Goldberg, D. M., andRoy, A. D. Trasylol and acute pancreatitis.Brit Med J 2: 943, 1965.

    Google Scholar 

  5. Grozinger, K. H., Hollis, A. V., andArtz, C. P. Experimental studies on the prevention of fatal pancreatitis.JAMA 187:652, 1964.

    Google Scholar 

  6. Haig, T. H. B., andThompson, A. G. The effect of a kallikrein inactivator on experimental acute pancreatitis.Canad J Surg 7:97, 1964.

    Google Scholar 

  7. Maurer, G. A new treatment for acute pancreatic disease—experiences with a trypsin inactivator.Med Press 27:287, 1961.

    Google Scholar 

  8. McCutcheon, A. D., andRace, D. Experimental pancreatitis: Use of a new antiproteolytic substance: Trasylol.Ann Surg 158:233, 1963.

    Google Scholar 

  9. McHardy, G., Craichead, C. C., Balart, L., Cradic, H., andLaGrange, C. Pancreatitis: Intrapancreatic proteolytic trypsin activity.JAMA 183: 527, 1963.

    Google Scholar 

  10. Moshal, M. G., Marks, I. N., Bank, S., andFord, D. A. A trial of Trasylol in the treatment of acute pancreatitis.S Afr Med J 37:1072, 1963.

    Google Scholar 

  11. Nemir, P., Hofericher, J., andDrabkin, D. L. The protective effect of proteinase inhibitor in acute necrotizing pancreatitis.Ann Surg 158:655, 1963.

    Google Scholar 

  12. Smith, R. B., Orahood, R. C., Wangensteen, S. L., Berakha, G. J., andZarelis, A. Effect of a trypsin inhibitor on experimentally induced pancreatitis in the dog.Surgery 54:922, 1963.

    Google Scholar 

  13. Skyring, A., Singer, A., andTornya, P. Treatment of acute pancreatitis with Trasylol.Brit Med J 2:627, 1965.

    Google Scholar 

  14. Trapnell, J. E. The natural history and prognosis of acute pancreatitis.Hunterian Lecture 1965. Ann Roy Coll Surg Eng 38:265, 1966.

    Google Scholar 

  15. Weiss, A. G., Hollander, L., andAdloff, M. Action of anti-enzymes on the evolution of acute pancreatitis.Mem Acad Chir 85:664, 1960.

    Google Scholar 

  16. Werle, E., Maurer, L., andRingelmann, E. Inhibition of proteinases by kallikrein inhibitors.Naturwissenschaften 39:328, 1952.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Royal Infirmary and Southmead Hospital, Bristol, England

    J. E. Trapnell M.D. (F.R.C.S.), C. H. Talbot M.Chir. (F.R.C.S.) & W. M. Capper (F.R.C.S.)

  2. the Royal Infirmary, Sheffield, England

    J. E. Trapnell M.D. (F.R.C.S.), C. H. Talbot M.Chir. (F.R.C.S.) & W. M. Capper (F.R.C.S.)

Authors
  1. J. E. Trapnell M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. H. Talbot M.Chir.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. M. Capper
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The Trasylol used in this study was supplied by Farbenfabriken Bayer A. G., Leverkusen, West Germany. Mr. G. H. Darling, F.P.S., made up the doses used in the blind trial and controlled its key.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trapnell, J.E., Talbot, C.H. & Capper, W.M. Trasylol in acute pancreatitis. Digest Dis Sci 12, 409–412 (1967). https://doi.org/10.1007/BF02241945

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02241945

Keywords

Search

Navigation